secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002742
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia reports preliminary Q4 2025 revenue $3.3M (+16% YoY); eliminates $26.9M debt
--------------------------------------------------------------------------------

- Preliminary Q4 net sales ~$3.3M, up 16% YoY, excluding divested BioEnvelope business.
- Repaid full $26.9M debt to SWK Holdings, significantly cutting interest expense.
- Cash on hand $36.3M; $8M escrow from BioEnvelope divestiture expected in 2026.
- Plans FDA filing for NXT-41 base matrix in H1 2026, clearance H2 2026; NXT-41x clearance H1 2027.
- CEO cites $88M EluPro divestiture to Boston Scientific as transformational, funding NXT-41x.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465926002742/0001104659-26-002742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465926002742/elut-20260112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer